AOA Dx is proud to announce that their Chief Scientific Officer, Prof. H. Uri Saragovi has been awarded a $650,000 CAD grant for further development of a proprietary liquid biopsy test for early stage ovarian cancer. AOA Dx has an exclusive license agreement to the proprietary technology. In addition to serving as AOA Dx’s Chief Scientific Officer, Prof. Saragovi is the Senior Investigator with the Lady Davis Institute at the Jewish General Hospital and Professor at McGill University
The funding will support ongoing development of AKRIVIS GD, a diagnostic test for ovarian cancer that is set to revolutionize early stage ovarian cancer diagnostics. The technology is based on a novel method of quantifying tumor marker gangliosides in blood. The grant submission was ranked #1 with a 100% rank within the committee, in a highly competitive round for funding from Canadian Institute of Health Research.
Proof of concept data shows that AKRIVIS GD liquid biopsy assay has both an excellent sensitivity and specificity, significantly superior to traditional diagnostic methods for early and late stage disease.
“We are honored to receive this grant and continue working with Prof. Saragovi to help create a better future for women diagnosed with ovarian cancer. Our goal is to work closely with scientific innovators to bring their findings to market and make them widely available to impact clinical practice today and improve standard of care.” Oriana Papin-Zoghbi, CEO and co-founder of AOA Dx.
About AOA Dx Inc.
AOA Dx Inc (AOA Inc) is a US company, with teams based in Boston, New York and London developing cancer diagnostics in the field of women’s health. AOA Dx Inc, a female led company, is committed to bringing the first accurate early stage liquid biopsy ovarian cancer diagnostic test to market that will improve clinical practice, help reduce patient mortality and deliver cost savings to payers. More information can be found at www.aoadx.com.